11
October

08:00 AM CEST

Cell & Gene Therapy

Strategy Meeting Europe 2022

Innovative Manufacturing, Clinical & Logistical Strategies to Boost Cell & Gene Therapy Efficacy and Accessibility to Patients

Radisson Blu Hotel, Zurich Airport

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Cell & Gene Therapy Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s Manufacturing Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Cell & Gene Therapy professionals from across Europe, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across Europe, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Cell & Gene Therapy Meeting.

Allan Van Konynenburg

Senior Director, Global Depot Network SanaClis

Feliks Kochan

Account Executive Business Development Manager Peli Biothermal

Eduard Ayuso

Chief Technical Officer Dinaquor

Giner Bjoern

MS&T Technical Steward Cell and Gene Therapy Novartis

Ivan Gorbachov

Senior Director Novartis Gene Therapies

Amir Goudarzi

Senior Director, Bioprocessing Technologies Bayer

Eric Halioua

Chief Executive Officer & President PDC*Line Pharma

Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with its different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, he has raised as of now a total of more than €160 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is President and CEO of the biotechnology company PDC-Line Pharma and board member of Cell Matters. He was also a Board Member of the French biotechnology company Vivalis/Valneva and the Belgian company Bioxodes, the Health Cluster of Wallonia BIOWIN and the industrial association European Biotechnology Entreprises (EBE).
Eric have been as well co-Inventor of the first worldwide GMP approved mobile manufacturing unit for cell therapy (WO 2014049151 A). He worked for 12 years as a Principal in the Healthcare and Life Sciences Practice of Arthur D. Little where he led work in the areas of strategy, M&A and technology & innovation management.
He is co-founder of 4 biotechnology companies called Myosix, Murigenetics, Digital-Orthopaedics and HairClone.
-Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been bought by Genzyme mid-2002. 
-Murigenetics is a Biotechnology company developing therapies for genetic disorders. 
-Digital Orthopaedics is a Digital Health company providing access to a comprehensive Clinical Decision Support System for musculoskeletal pathologies. 
-HairClone is a Biotechnology company developing cell-based hair treatments and Follicle Banking Service.
Eric worked for IsoHealthcare Group (eventually acquired by the Monitor Group) as a Senior Consultant where I focused on leading healthcare and life sciences issues. He also worked as a strategic marketing Manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Zeneca in UK.
Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.

Steen Klysner

CEO Amarna Therapeutics

Steen Klysner is Chief Executive Officer at <a href="https://www.amarnatherapeutics.com/">Amarna Therapeutics</a>. Steen Klysner comes to Amarna with over 30 years of experience in the life sciences industry. Prior to joining Amarna, Dr. Klysner served as CEO of the Swedish ExpreS2ion Biotech Holding AB in parallel with the Danish ExpreS2ion Biotechnologies ApS. Earlier, he was Senior Vice President (SVP) of preclinical R&D and SVP of Quality of Allergopharma, the Allergy Business Unit of Merck KGaA. He also served as CEO of Nordic Vaccine in Copenhagen, focusing on the development of non-invasive vaccination based on an integrated nanoparticle adjuvant and delivery platform. Prior to that he has also held positions at Pharmexa, Novo Nordisk and ALK. 
Dr. Klysner holds a Ph.D. from Technical University of Denmark combined with an Industrial Scientist Research Degree from the Danish “Academy of Technical Sciences”, a M.Sc. degree in Biochemistry from the University of Copenhagen and a B.Sc. in sports from the University of Copenhagen. Finally, Dr. Klysner is author/co-author of numerous patents and scientific publications in (inter)-national peer-reviewed medical journals.

Dorothea Ledergerber

Chief Technical Officer Tigen Pharma

Peter Tiefenböck

Associate Director, Value Stream Leader PU Cell & Gene Therapy Novartis

I-Mei Yu

Principle Scientist, RNA & Gene Therapy | Drug Discovery | Precision Therapy Novo Nordisk

Michael Zaiac

Head of Medical Affairs Oncology Region Europe Novartis

First name	Last name	Job title	Company name	Photo URL	Bio Position
Allan	Van Konynenburg	Senior Director, Global Depot Network	SanaClis	https://proventainternational.com/wp-content/uploads/2022/09/Allan-van-Konynenburg.jpg	Allan van Konynenburg has more than two decades of experience in Business Development and Operations in the pharmaceutical arena, specifically in specialty logistics and supply chain. He brings with him a wealth of knowledge and experience across the pharmaceutical ecosystem, extending to Warehousing, Fulfilment, Distribution, CTSM, Logistics, Direct-to-patient, and Cell & Gene therapy. Allan is responsible for SanaClis vendor relationships, identification of specialized Clinical Trial Depots, formalization of business relationship with current and new vendors and establishing and negotiation of unified pricing models. His knowledge and experience play a key role in managing innovative approaches to existing and new business challenges and work with teams across SanaClis to deliver customer-centric products and services that support SanaClis’ mission statement.
Feliks	Kochan	Account Executive Business Development Manager	Peli Biothermal	https://proventainternational.com/wp-content/uploads/2022/09/Feliks-Kochan.jpg	Feliks joined Peli BioThermal in 2021 and is responsible for selling and developing the company’s range of NanoCool products to the Pharmaceutical market within EMEA. He has extensive experience within the Biotech and novel medicines sector gained over a number of years in the field, modification of viral vectors for gene therapy applications in particular
Eduard	Ayuso	Chief Technical Officer	Dinaquor	https://proventainternational.com/wp-content/uploads/2022/07/Eduard-Ayuso-New.jpg	Dr. Eduard Ayuso is an expert in the field of gene therapy using viral vector platforms and serves as Chief Technology Officer at DiNAQOR. With more than 50 scientific publications and more than two decades of academic and industry consulting experience, Dr. Ayuso has made significant contributions to the field of in vivo gene transfer in small and large animal models of diseases, as well as AAV vector development and analytics. He has served as Head of Innovative Vectorology at the French National Institute of Health and Medical Research (INSERM), and as the Scientific Director of the Translational Vector Core unit at University of Nantes. He currently serves as Vice President of the French Society for Gene and Cell Therapy. Dr. Ayuso earned his PhD in Biochemistry and Molecular Biology and his DVM from Autonomous University of Barcelona.
Giner	Bjoern	MS&T Technical Steward Cell and Gene Therapy	Novartis	https://proventainternational.com/wp-content/uploads/2022/09/Bjoern-Giner.jpg	13 years with Novartis Pharma AG. 9 years of does working in Cell and Gene Therapy in several functions in Development, Production Unit and Manufacturing Science & Technologies (MS&T) currently as Technical Steward. Started the CGT journey in Morris Plains US for Novartis by supporting the Tech Transfer from University of Pennsylvania to a GMP Facility of Novartis of the first CART therapy as well as launching it commercial in the US and abroad. Since 4 years in Switzerland Stein located for launching the therapy for EMA and support routine manufacturing as well as new technologies.
Ivan	Gorbachov	Senior Director	Novartis Gene Therapies	https://proventainternational.com/wp-content/uploads/2022/08/Ivan-Gorba.jpg
Amir	Goudarzi	Senior Director, Bioprocessing Technologies	Bayer	https://proventainternational.com/wp-content/uploads/2022/07/Amir-Goudarzi235x235.png	Amir Goudarzi has more than 15 years of experience in the bioprocess industry. In his latest role at UCB Pharma in Belgium, Amir lead global tech transfer of (early to late stage) biologics from development labs to pilot to full commercial scale. Amir & his team look after addressing industrialization of these processes by tackling manufacturing challenges, scale up/scale down rationals, automation integrations and plant engineering aspects at UCB’s internal & external BioDS manufacturing sites. With broader UCB development teams, Amir devised the long range development & investment plans for UCB to enable implementation of state of the art bioprocesses in state of the art facilities at UCB. As of May-2022, as Sr Director BioProcess Technologies, Amir will join Bayer’s global advanced manufacturing teams with focus on CGT/mAbs DS & DP processes.
Eric	Halioua	Chief Executive Officer & President	PDC*Line Pharma	https://proventainternational.com/wp-content/uploads/2020/01/Eric-Halioua-1.jpg	Serial entrepreneur that combines strong strategic, technological and managerial experience with proven track record of deal-making and fund-raising. During his career he achieved together with its different teams to bring four drug candidates from research to the clinics (up to phase IIb). Overall, he has raised as of now a total of more than €160 million from VCs and strategic partners in Europe, USA, Japan and Korea and have had numerous successes in the sale and initial public offering of biotechnology companies. He is President and CEO of the biotechnology company PDC-Line Pharma and board member of Cell Matters. He was also a Board Member of the French biotechnology company Vivalis/Valneva and the Belgian company Bioxodes, the Health Cluster of Wallonia BIOWIN and the industrial association European Biotechnology Entreprises (EBE). Eric have been as well co-Inventor of the first worldwide GMP approved mobile manufacturing unit for cell therapy (WO 2014049151 A). He worked for 12 years as a Principal in the Healthcare and Life Sciences Practice of Arthur D. Little where he led work in the areas of strategy, M&A and technology & innovation management. He is co-founder of 4 biotechnology companies called Myosix, Murigenetics, Digital-Orthopaedics and HairClone. -Myosix is a tissue engineering company specialising in musculoskeletal cells culture used in the regeneration of the heart muscle. The company has been bought by Genzyme mid-2002. -Murigenetics is a Biotechnology company developing therapies for genetic disorders. -Digital Orthopaedics is a Digital Health company providing access to a comprehensive Clinical Decision Support System for musculoskeletal pathologies. -HairClone is a Biotechnology company developing cell-based hair treatments and Follicle Banking Service. Eric worked for IsoHealthcare Group (eventually acquired by the Monitor Group) as a Senior Consultant where I focused on leading healthcare and life sciences issues. He also worked as a strategic marketing Manager for the “Centre Européen de Bioprospective” and as project leader in the corporate R&D centre of Zeneca in UK. Eric holds two master degrees (DEA and Magistère) in Pharmacology and Molecular Biology and a MBA from ESSEC business school (Paris, France), with an advanced degree from the Health Care ESSEC chair.
Steen	Klysner	CEO	Amarna Therapeutics	https://proventainternational.com/wp-content/uploads/2022/08/Steen-Klysner.jpg	Steen Klysner is Chief Executive Officer at Amarna Therapeutics. Steen Klysner comes to Amarna with over 30 years of experience in the life sciences industry. Prior to joining Amarna, Dr. Klysner served as CEO of the Swedish ExpreS2ion Biotech Holding AB in parallel with the Danish ExpreS2ion Biotechnologies ApS. Earlier, he was Senior Vice President (SVP) of preclinical R&D and SVP of Quality of Allergopharma, the Allergy Business Unit of Merck KGaA. He also served as CEO of Nordic Vaccine in Copenhagen, focusing on the development of non-invasive vaccination based on an integrated nanoparticle adjuvant and delivery platform. Prior to that he has also held positions at Pharmexa, Novo Nordisk and ALK. Dr. Klysner holds a Ph.D. from Technical University of Denmark combined with an Industrial Scientist Research Degree from the Danish “Academy of Technical Sciences”, a M.Sc. degree in Biochemistry from the University of Copenhagen and a B.Sc. in sports from the University of Copenhagen. Finally, Dr. Klysner is author/co-author of numerous patents and scientific publications in (inter)-national peer-reviewed medical journals.
Dorothea	Ledergerber	Chief Technical Officer	Tigen Pharma	https://proventainternational.com/wp-content/uploads/2022/09/Dorothea-Ledergerber.jpg	Dorothea is a pharmacist with more than 20 years of experience in research, development, manufacturing and supply of pharmaceutical products. She received her PhD from the University of the Saarland, Saarbrücken, Germany. While with Novartis, she was leading manufacturing sites in Switzerland, Germany and Ireland. A highlight in her career was the build-up and operational launch of the first commercial Cell & Gene manufacturing facility for Novartis in Europe. In 2020, Dorothea moved on to Tigen Pharma, a Swiss biotech company in the field of cell therapies to cure cancer. Tigen is a disruptive catalyst, combining a unique culture with a multidisciplinary set of clinical and technical capabilities and a long-term perspective to the benefit of patients and society. Dorothea is a firm believer in cross-cultural and -functional teams to go beyond the beaten industry track.
Peter	Tiefenböck	Associate Director, Value Stream Leader PU Cell & Gene Therapy	Novartis	https://proventainternational.com/wp-content/uploads/2022/09/Peter-Tiefenbock.jpg
I-Mei	Yu	Principle Scientist, RNA & Gene Therapy \| Drug Discovery \| Precision Therapy	Novo Nordisk	https://proventainternational.com/wp-content/uploads/2022/08/I-Mei-Yu-NEW-1.jpg
Michael	Zaiac	Head of Medical Affairs Oncology Region Europe	Novartis	https://proventainternational.com/wp-content/uploads/2020/08/Michael-Z.jpg	Michael pursued a postgraduate career in Surgery and Surgical Oncology in the UK and in Germany gaining an MD in myocardial preservation in 1989 and an FRCS in 1992. Since joining the pharmaceutical Industry in 1994 he covered roles of increasing responsibility in clinical research, medical affairs and strategic marketing and participated in new medicines launches, large development programmes for small molecules and monoclonal antibodies and the day-to-day management of medical affairs at country, regional and global level. He has published on surgery, breast cancer, sarcoma targeted small molecules, mToR and general aspects of pharmaceutical medicine.

Allan Van Konynenburg, Feliks Kochan, Eduard Ayuso, Giner Bjoern, Ivan Gorbachov, Amir Goudarzi, Eric Halioua, Steen Klysner, Dorothea Ledergerber, Peter Tiefenböck, I-Mei Yu, Michael Zaiac

See the complete agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Who Should Attend the Event?

Chief Executive Officers

Chief Medical Officer

Chief Scientific Officer

Senior Vice Presidents

Vice Presidents

Executive Directors

Global Heads

Directors

Executive Director

Responsible For:

Cell Therapy

Cell Engineering

Biotherapeutics

Regenerative Medicine

Immune Deficiencies

CART

Cellular Immunotherapy

Supply Chain

Manufacturing

AAV

Lentivectors

TCR Cell Immunotherapies

mRNA/DNA

CRISPR/CAS

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

Addressing Challenges Posed in vivo by AAV Vectors: The Quest for the ‘Perfect’ Toolkit

iPSC-Derived Allogeneic Cell Therapies to address disease-specific challenges

Discussing Strategies to Increase Manufacturability of Allogeneic Cell Therapies

Enabling cell and gene therapy clinical development by addressing evidence generation and research reproducibility

Reworking logistics for cell and gene therapy

11:00 – 12:00

Roundtable Tracks

Addressing challenges in Vivo by AAV Vectors- Searching for the ‘Perfect’ toolkit

Autologous vs. Allogeneic Cells: Optimizing ‘Off-The- Shelf’ Therapeutics

Meeting the Manufacturing Challenges of Cell & Gene Therapies–To Buy Or Build

Practical Consideration for Adoption, Accelerating and the Future of Cell and Gene Therapy SANACLIS

The importance of High Quality Temperature Controlled Packaging When Shipping Cell & Gene Therapies PELI BIOTHERMAL

Reasons To Attend the Strategy Meeting

Explore the future of cell-based immunotherapy: autologous vs allogeneic treatment

Novel insights into the new class of CAR T-cells on the horizon that can target previously untargetable cancer drivers

Investigate strategies on how to overcome AAV innate immunity barriers to further gene therapy development

Discuss key considerations when designing clinical trials for rare diseases in gene therapy

Press play to hear what your colleagues had to say...

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

Manufacturing Europe

Clinical Operations & Clinical Trial Supply Chain Strategy Meeting Europe 2026

Cell & Gene Therapy

Strategy Meeting Europe 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Radisson Blu Hotel, Zurich Airport

Fresh Cell & Gene Therapy Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our 2022 Facilitators

Allan Van Konynenburg

Feliks Kochan

Eduard Ayuso

Giner Bjoern

Ivan Gorbachov

Amir Goudarzi

Eric Halioua

Steen Klysner

Dorothea Ledergerber

Peter Tiefenböck

I-Mei Yu

Michael Zaiac

See the complete agenda and facilitator line-up

Who Should Attend the Event?

Chief Executive Officers

Chief Medical Officer

Chief Scientific Officer

Senior Vice Presidents

Vice Presidents

Executive Directors

Global Heads

Directors

Executive Director

Responsible For:

Cell Therapy

Cell Engineering

Biotherapeutics

Regenerative Medicine

Immune Deficiencies

CART

Cellular Immunotherapy

Supply Chain

Manufacturing

AAV

Lentivectors

TCR Cell Immunotherapies

mRNA/DNA

CRISPR/CAS

See Which Topics Are Discussed at the Strategy Meeting

REGISTRATION AND WELCOME

OPENING KEYNOTE PRESENTATION An overview of biologics supplies also in light of the pandemic challenges and emergence of multiple new biologics modality

Roundtable

Roundtable Tracks

Addressing Challenges Posed in vivo by AAV Vectors: The Quest for the ‘Perfect’ Toolkit

iPSC-Derived Allogeneic Cell Therapies to address disease-specific challenges

Discussing Strategies to Increase Manufacturability of Allogeneic Cell Therapies

Enabling cell and gene therapy clinical development by addressing evidence generation and research reproducibility

Reworking logistics for cell and gene therapy

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

NETWORKING / 1-1 MEETINGS

Roundtable

Roundtable Tracks

Addressing challenges in Vivo by AAV Vectors- Searching for the ‘Perfect’ toolkit

Autologous vs. Allogeneic Cells: Optimizing ‘Off-The- Shelf’ Therapeutics

Meeting the Manufacturing Challenges of Cell & Gene Therapies–To Buy Or Build

Practical Consideration for Adoption, Accelerating and the Future of Cell and Gene Therapy SANACLIS

The importance of High Quality Temperature Controlled Packaging When Shipping Cell & Gene Therapies PELI BIOTHERMAL

NETWORKING LUNCH

Reasons To Attend the Strategy Meeting

Radisson Blu Hotel, Zurich Airport

OPENING KEYNOTE PRESENTATION
An overview of biologics supplies also in light of the pandemic challenges and emergence of multiple new biologics modality